As the world's first GIP/GLP-1 dual receptor agonist pharmaceutical raw material, Tirzepatide is crafted via advanced synthesis and purification, with =95% bioavail ability. Unlike single-target metabolic drugs, its core edge is dual-receptor co-activation, breaking single-target GLP-1 efficacy limits to synergize weight loss and blood glucose control, with longer-lasting results and lower blood glucose fluctuation risk.
link:http://www.lymallpanda.com